Immunotherapy has shown only modest clinical efficacy in breast cancer, and PD-L1 expression has been shown to be associated with TIL infiltration and better clinical outcomes (Cimino-Mathews et al., 2016). The gene discussed is CD274; the disease is breast cancer.